Metabolic

Metabolic research peptides are the most closely watched compounds in current peptide science, and this category maps the whole receptor landscape rather than a single product line. Understanding which receptors a compound engages is the first decision in any study design here.
The incretin series, by receptor count
Semaglutide is the single agonist, acting on the GLP-1 receptor alone, with the deepest published literature in the class and the natural baseline for comparative work. Tirzepatide is the dual agonist, adding GIP receptor activity to the same molecule. Retatrutide extends the series to three, adding glucagon receptor activity on top of both. Our retatrutide versus tirzepatide comparison covers the structural and practical differences in detail, and a combined retatrutide and tirzepatide vial serves co-exposure designs.
The compound outside that series
Cagrilintide belongs to a different hormone system entirely. It is a long-acting amylin analogue acting on amylin receptors, built from the calcitonin receptor paired with modifying proteins, not on incretin receptors at all. That is why it is studied alongside semaglutide rather than instead of it: the two engage separate, complementary pathways. For research mapping metabolic signaling broadly, it is the piece the incretin series cannot substitute for.
Verification in a crowded market
Demand for these compounds has pulled a great deal of unverified material into circulation, which makes documentation the entire game. Every product here is tested by an independent analytical laboratory, purity by HPLC and identity by mass spectrometry, with certificates published in our COA portal for review before purchase. Our supplier vetting guide gives you the checklist. All compounds are sold for laboratory research use only.